



SafeClick™ – Aqueo

- SafeClick™ - Aqueo is Future Injection Technology's (FIT's) proprietary single use auto-injector for aqueous drugs.
- SafeClick™ - Designed from first principles to protect the delicate syringes from breakage.
- SafeClick™ - enables self-administration of subcutaneous (sc) and intramuscular (im) injections using your existing pre-filled syringes and cartridges. No change to the primary drug-pack enables a low cost and fast route to market via CE marking/510k or equivalent.

Key Features

- Unique proprietary mechanism that completely prevents syringe breakage
- Delivery of any aqueous injectable formulations
- Any fill or delivery volume from 0.1ml upwards
- Fully automatic needle protection inside the sturdy device with no need for a needle shield
- Entire therapeutic dose is delivered at correct needle depth
- Simple and fully automatic with simple two step activation
- Takes any type or size of syringe or cartridge both glass and plastic
- Delivery time can be tailored
- Steady flow rate through entire injection of dose
- Design and additional safety features allow easy use by musculoskeltally impaired patients
- Delivery of viscous injectable drug formulations in excess of 1000 centipoises.
- Audible clicks at beginning and end of injection
- Proprietary primary and secondary packaging ensures SafeClick™ functions perfectly only when required
- Huge time and cost savings in development as SafeClick™ uses existing syringes.
- Low cost manufacture – only seven plastic components.

SafeClick™ Aqueo

Novel design for high viscosity

SafeClick™ was designed from first principles to protect syringes from breakage and has 4 unique design features that prevent the syringes and the vulnerable finger flanges from breaking.

Requirement for auto-injectors

Primary healthcare costs can be reduced by up to 95% if patients can self-administer their injectable medicines as they no longer have to attend a clinic for administration of the injection by a healthcare professional. In addition, needle safe auto-injectors such as SafeClick™ have been shown to reduce needle-stick injuries, estimated at 500 thousand to 1 million injuries per year in the US, by up to 85%.

Use of existing and approved pre-filled syringes

SafeClick™ uses existing pre-filled syringes that are already approved for therapeutic use. This means that minimal regulation is required for use with injectable medicines. SafeClick™ offers an immediate solution for self-administration comprising a pre-filled syringe that is packaged within the SafeClick™ device as a single use disposable product.

Regulatory needle-stick compliance

SafeClick™ has fully automatic needle protection with the needle retained inside the sturdy device before and after injection. It has been designed to comply with the emerging needle-stick regulations that are making needle safe devices mandatory.

Protection of Pharmaceutical product franchises

The ability for patients to self-medicate with needle safe devices is a key market differentiator for injectable pharmaceuticals. Self-medication offers huge cost savings to healthcare providers and dramatic lifestyle benefits for patients. Access to a proprietary auto-injector such as SafeClick™ is essential to gaining and maintaining product market share.

Confirmed administration

Administration is confirmed by audible clicks at the beginning and end of the injection cycle. A full length viewing window shows that the medication has been administered.



High reliability

Misfiring caused by incorrect handling or abuse during transportation is prevented by proprietary primary and secondary packaging and automated safety features. The unique and proprietary mechanism overcomes the failures inherent with other product offerings, particularly their inability to offer 100% syringe protection.

Designed for musculoskeletally impaired patients

The design is aimed at optimizing patient acceptance and affinity with the device. Activation is by removal of the ergonomically designed end-cap, optimized for patients with impaired dexterity. Simply pushing the device against the skin activates the injection mechanism.

Huge development cost savings

SafeClick™ offers a low cost and fast route to market compared to alternative new, unapproved and high risk routes of delivery. Use of industry standard syringes within the device precludes the need for additional large, expensive and time consuming clinical trials.

Low cost manufacture

SafeClick™ is manufactured by existing and well proven injection moulding techniques on single or multi-cavity splits. The small number of highly robust components ensures low manufacturing and assembly costs.

Partnering Opportunity

FIT is seeking partners with drugs on the market or in development to accelerate and diversify the use of SafeClick™ with new and existing aqueous injectable medicines. Key application areas include, generics and bio-similars in pre-filled syringes that are seeking product differentiation in the market, proprietary biologics such as antibody based drugs, vaccines and in particular pandemic management and defense use for administration of battlefield medicines.

Contact

Paul Whyte, Chief Executive Officer
Future Injection Technologies Limited
The Magdalen Centre
Oxford, UK
OX4 4GA

Web www.futureinjection.com
Email paul@futureinjection.com
Tel +44 (0) 01865 784555
Mob +44 (0) 7738 026 703
Fax +44 (0) 01865 784004